Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon

IMPORTANCE: Calcitonin gene-related peptide (CGRP) antagonists have demonstrated tremendous promise in migraine management. However, these medications decrease reflex vasodilatory response, which may lead to exacerbation of microvascular disease in susceptible patients, such as patients with Raynaud...

Descripción completa

Detalles Bibliográficos
Autores principales: Breen, Ilana D., Brumfiel, Caitlin M., Patel, Meera H., Butterfield, Richard J., VanderPluym, Juliana H., Griffing, Leroy, Pittelkow, Mark R., Mangold, Aaron R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056280/
https://www.ncbi.nlm.nih.gov/pubmed/33871613
http://dx.doi.org/10.1001/jamanetworkopen.2021.7934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056280/
https://www.ncbi.nlm.nih.gov/pubmed/33871613
http://dx.doi.org/10.1001/jamanetworkopen.2021.7934

Ejemplares similares